This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wyman, A. Articles by Moley, K. H. Search for Related Content PubMed PubMed Citation Articles by Wyman, A. Articles by Moley, K. H.

One-Cell Zygote Transfer from Diabetic to Nondiabetic Mouse Results in Congenital Malformations and Growth Retardation in Offspring

Department of Obstetrics and Gynecology (A.W., R.S., K.H.M.), Washington University School of Medicine, St. Louis, Missouri 63110; and Department of Obstetrics and Gynecology (A.B.P.), Baylor University Medical Center, Dallas, Texas 75246

Address all correspondence and requests for reprints to: Kelle H. Moley, M.D., Professor and Vice Chair of Obstetrics and Gynecology, Washington University in St. Louis, 660 South Euclid Avenue, St. Louis, Missouri 63110. E-mail: moleyk{at}wustl.edu.

Fetuses of type 1 and 2 diabetic women experience higher incidences of malformations and fetal death as compared with nondiabetics, even when they achieve adequate glycemic control during the first trimester. We hypothesize that maternal diabetes adversely affects the earliest embryonic stage after fertilization and programs the fetus to experience these complications. To test this hypothesis, we transferred either one-cell mouse zygotes or blastocysts from either streptozotocin-induced diabetic or control mice into nondiabetic pseudopregnant female recipients. We then evaluated the fetuses at embryonic d 14.5 to assess fetal growth and the presence or absence of malformations. We found that fetuses from the diabetic mice transferred at the blastocyst stage but also as early as the one-cell zygote stage displayed significantly higher rates of malformations consistent with neural tube closure problems and abdominal wall and limb deformities. In addition, both these groups of fetuses were significantly growth retarded. To determine if this phenomenon was due to high glucose concentrations, two-cell embryos were cultured to a blastocyst stage in 52 mM D-glucose or L-glucose as an osmotic control, transferred into nondiabetic pseudopregnant mice, and examined at embryonic d 14.5. These embryos did not demonstrate any evidence of malformations, however, they did experience significantly higher rates of resorptions, lower implantation rates, and they were significantly smaller at embryonic d 14.5. In summary, exposure to maternal diabetes during oogenesis, fertilization, and the first 24 h was enough to program permanently the fetus to develop significant morphological changes.

This article has been cited by other articles:

				Q. Wang, A. M. Ratchford, M. M.-Y. Chi, E. Schoeller, A. Frolova, T. Schedl, and K. H. Moley Maternal Diabetes Causes Mitochondrial Dysfunction and Meiotic Defects in Murine Oocytes Mol. Endocrinol., October 1, 2009; 23(10): 1603 - 1612. [Abstract] [Full Text] [PDF]

				S Schmidt, A Hommel, V Gawlik, R Augustin, N Junicke, S Florian, M Richter, D J Walther, D Montag, H-G Joost, et al. Essential role of glucose transporter GLUT3 for post-implantation embryonic development J. Endocrinol., January 1, 2009; 200(1): 23 - 33. [Abstract] [Full Text] [PDF]

				I. A. Simpson, D. Dwyer, D. Malide, K. H. Moley, A. Travis, and S. J. Vannucci The facilitative glucose transporter GLUT3: 20 years of distinction Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E242 - E253. [Abstract] [Full Text] [PDF]